Dana-Farber Cancer Institute
44 Binney Street
Boston
Massachusetts
02115
United States
Tel: 617-632-3000
301 articles with Dana-Farber Cancer Institute
-
President Joe Biden has nominated former U.S. Food and Drug Administration Commissioner Robert Califf to reprise his role at the agency’s helm.
-
David Morse Livingston, a giant in oncology research known for his significant contributions to translational cancer research, unexpectedly died. He was 80.
-
This followed a report that found that some trustees had, perhaps, taken advantage of this close connection with startups and research programs for their financial gain.
-
The FDA awarded a number of designations for Takeda's candidate drug EXKIVITY in the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer.
-
The approval was built on data from the Phase III ASPEN trial that compared Brukinsa to ibrutinib in a total of 201 patients with MYD88 mutation.
-
ZN-c3 is a WEE1 inhibitor that could be used as monotherapy for uterine serous carcinoma and solid tumors, as well as combination therapy for ovarian cancer, alongside chemotherapy.
-
SpringWorks has announced a research collaboration with the Dana-Farber Cancer Institute to advance its therapy development efforts for multiple myeloma and related diseases.
-
Harbour BioMed and Dana-Farber Cancer Institute Collaborate to Advance Novel Biotherapies for Cancer Treatment
6/16/2021
Harbour BioMed announced it has entered into a multi-year, multifaceted research collaboration agreement with Dana-Farber Cancer Institute to co-develop novel biotherapies in cancer treatment.
-
The research collaboration will see the development of bispecific antibodies and CAR-T cell products.
-
Grail presents its first data from the interventional PATHFINDER trial of Galleri, its multi-cancer early detection blood test. Galleri is now available in the U.S. by prescription.
-
Dana-Farber Cancer Institute Announces $2 Billion Fundraising Campaign to Defy Cancer
5/18/2021
Dana-Farber Cancer Institute announced the most ambitious fundraising campaign in its history, and the largest campaign ever in New England focused entirely on cancer.
-
JNCCN: New Evidence on Need to Address Muscle Health among Patients with Cancer
3/9/2021
Results of new study from Mass General Hospital Cancer Center, Harvard Medical School, and Dana-Farber Cancer Institute underscore the need for the development and testing of nutrition and fitness interventions, as muscle quality significantly correlates with symptom burden, healthcare utilization, and survival.
-
Dana-Farber Cancer Institute and Deerfield Management Launch Riverway Discoveries
2/8/2021
Dana-Farber Cancer Institute and Deerfield Management Company, a healthcare investment management firm focused on advancing healthcare through investment, information and philanthropy, have formed a major translational research partnership to accelerate the development of therapeutics and diagnostics for cancer.
-
The duo launch Riverway Discoveries to drive the development and commercialization of new cancer therapeutics faster into patient's hands.
-
Foundation Medicine and Dana-Farber Present Data at ASCO20 Showing that Comprehensive Genomic Profiling Identified Co-Occurring Alterations that May Cause Treatment Resistance in Patients with METex14-altered NSCLC
5/29/2020
Alterations that cause skipping of exon 14 on the MET gene (METex14) are drivers of a type of lung cancer with a poor prognosis, but that is treatable with a recently approved MET inhibitor
-
Crown Bioscience Expands PDX Collection with Acquisition of Unique Models from Leading Academic Medical Centers
4/2/2020
Agreements with CoMotion at the University of Washington and Dana-Farber Cancer Institute add new prostate cancer and lymphoma models to the world’s largest PDX collection
-
It will combine MPM’s venture capital investment fundraising with Dana-Farber’s philanthropic fundraising for cancer research.
-
Clinical Catch-Up: February 10-14
2/17/2020
It was a very busy week for clinical trial news. Here’s a look. -
The study was in 55 patients who had an average of three previous treatment regimens. The results are promising enough that a Phase III trial is planned.
-
Vanderbilt Oncologists Publish Results of First Study to Demonstrate Clinical Utility of Resolution Liquid Biopsy Assay to Monitor Response and Resistance to Ensartinib
10/29/2019
New Journal of Thoracic Oncology publication concludes prospective application of technology may translate to improved outcomes for non-small cell lung cancer patients